Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

A number of other research firms have also commented on SNY. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Monday, April 20th. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Trading Down 0.3%

Shares of NASDAQ SNY opened at $42.95 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68. The company has a market cap of $104.13 billion, a price-to-earnings ratio of 22.49, a P/E/G ratio of 1.15 and a beta of 0.35. The business has a fifty day simple moving average of $43.41 and a 200-day simple moving average of $45.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Fiduciary Financial Group LLC increased its stake in Sanofi by 33.8% in the 2nd quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock valued at $358,000 after buying an additional 2,124 shares during the period. Fulton Bank N.A. boosted its stake in shares of Sanofi by 5.6% during the 2nd quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock valued at $2,909,000 after buying an additional 3,623 shares during the period. First Bank & Trust grew its holdings in shares of Sanofi by 23.4% during the 2nd quarter. First Bank & Trust now owns 83,933 shares of the company’s stock valued at $3,581,000 after acquiring an additional 15,937 shares in the last quarter. Focus Financial Network Inc. grew its holdings in shares of Sanofi by 9.2% during the 2nd quarter. Focus Financial Network Inc. now owns 5,302 shares of the company’s stock valued at $226,000 after acquiring an additional 446 shares in the last quarter. Finally, Valeo Financial Advisors LLC increased its stake in shares of Sanofi by 11.0% in the second quarter. Valeo Financial Advisors LLC now owns 5,730 shares of the company’s stock worth $244,000 after acquiring an additional 568 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.